BCM
MIST icon

Bronte Capital Management’s Milestone Pharmaceuticals MIST Stock Holding History

Bronte Capital Management’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4K Hold
10,414
– – ﹤0.01% 52
2025
Q4 		$21K Buy
+10,414
New +$22.4K ﹤0.01% 42

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Bronte Capital Management's MIST Position: Q1 2026 in Review

Bronte Capital Management held its Milestone Pharmaceuticals (MIST) position steady in Q1 2026 at 10,414 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #52.

Bronte Capital Management first reported a position in MIST in Q4 2025 and has held it in 2 quarters since. The position peaked at $21K in Q4 2025. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Bronte Capital Management held 10,414 shares of Milestone Pharmaceuticals worth $12.4K as of Q1 2026.
  • Bronte Capital Management left its Milestone Pharmaceuticals share count unchanged in Q1 2026.
  • Milestone Pharmaceuticals made up ﹤0.01% of Bronte Capital Management's portfolio in Q1 2026, its #52 holding.
  • Bronte Capital Management first reported a position in Milestone Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Bronte Capital Management's Milestone Pharmaceuticals position peaked at $21K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Bronte Capital Management's 13F filing for Q1 2026, filed 27 Apr 2026.